Leerink Partnrs Forecasts Enhabit's Q4 Earnings (NYSE:EHAB)

Enhabit, Inc. (NYSE:EHAB - Free Report) - Analysts at Leerink Partnrs raised their Q4 2025 earnings estimates for Enhabit in a research report issued to clients and investors on Monday, November 18th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of $0.08 for the quarter, up from their prior forecast of $0.05. The consensus estimate for Enhabit's current full-year earnings is $0.25 per share.

Enhabit (NYSE:EHAB - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $253.60 million during the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same period in the previous year, the company earned $0.03 EPS.

Separately, Leerink Partners reissued a "market perform" rating and set a $8.00 target price (down from $8.50) on shares of Enhabit in a report on Tuesday. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company's stock. Based on data from MarketBeat, Enhabit has a consensus rating of "Hold" and a consensus price target of $9.25.

Enhabit Price Performance

EHAB traded up $0.12 on Wednesday, reaching $7.39. The stock had a trading volume of 202,083 shares, compared to its average volume of 579,459. The company has a market capitalization of $371.60 million, a price-to-earnings ratio of -3.13 and a beta of 1.84. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The firm has a 50-day moving average of $7.54 and a 200-day moving average of $8.43. Enhabit has a fifty-two week low of $6.85 and a fifty-two week high of $11.74.

Insider Buying and Selling

In related news, Director Jeffrey Bolton acquired 5,000 shares of the company's stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average price of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the acquisition, the director now owns 78,877 shares of the company's stock, valued at approximately $631,804.77. This trade represents a 6.77 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Enhabit

Large investors have recently added to or reduced their stakes in the business. SummerHaven Investment Management LLC boosted its holdings in Enhabit by 2.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company's stock valued at $549,000 after purchasing an additional 1,660 shares during the period. FMR LLC grew its holdings in shares of Enhabit by 138.4% during the third quarter. FMR LLC now owns 3,388 shares of the company's stock worth $27,000 after purchasing an additional 1,967 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Enhabit by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company's stock worth $443,000 after purchasing an additional 2,078 shares during the last quarter. Quarry LP raised its position in shares of Enhabit by 242.2% during the 2nd quarter. Quarry LP now owns 3,703 shares of the company's stock valued at $33,000 after buying an additional 2,621 shares in the last quarter. Finally, Gladius Capital Management LP lifted its stake in Enhabit by 78.2% during the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company's stock worth $49,000 after purchasing an additional 2,747 shares during the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.